NOROO Holdings Advances Commercialization of Bio-Based 3-HP Through Major Korean Government Initiative

NOROO Holdings Advances Commercialization of Bio-Based 3-HP Through Major Korean Government Initiative

Selected as the lead organization for a major government-backed initiative to accelerate commercialization of bio-based 3-HP through pilot-scale investments. Establishing an integrated R&D value chain spanning feedstock development, production,...

HL Mando Selected as GM's Supplier of the Year for Six Years in a Row

HL Mando Selected as GM's Supplier of the Year for Six Years in a Row

12 awards in total, highlighting the company's competitiveness based on its North American production base SEOUL, South Korea, June 9, 2026 /PRNewswire/ -- HL Mando, the global software-defined vehicle leader under HL Group, has been selected as a...

Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Selected for Oral Presentation at WCLC 2026, Demonstrating Sustained Breakthrough Efficacy Signals in NSCLC

Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Selected for Oral Presentation at WCLC 2026, Demonstrating Sustained Breakthrough Efficacy Signals in NSCLC

NANJING, China, May 28, 2026 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced that the Phase II clinical study of its proprietary PD-L1/4-1BB bispecific antibody, Opamtistomig...

Over 40 Studies Featuring Akeso's Innovative Oncology Agents to Be Presented at ASCO 2026: Ivonescimab's HARMONi-6 Overall Survival Data Selected for Plenary Session

Over 40 Studies Featuring Akeso's Innovative Oncology Agents to Be Presented at ASCO 2026: Ivonescimab's HARMONi-6 Overall Survival Data Selected for Plenary Session

HONG KONG, May 26, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that more than 40 clinical studies of its oncology portfolio will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual...

Clarivate's IPfolio and Renewal Services Selected by IGT

Clarivate's IPfolio and Renewal Services Selected by IGT

Managing global intellectual property more efficiently with trusted data, expert support and integrated services LONDON, May 21, 2026 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today...

Clarivate Selected By Czech National Library of Technology to Develop Unified National Library Platform

Clarivate Selected By Czech National Library of Technology to Develop Unified National Library Platform

New cloud-based, shared platform based on Alma and Primo to help National Library of Technology advance library services and information accessibility LONDON, May 19, 2026 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of...

HoneyNaps Selected for Korea's 2026 Global ICT Unicorn Program

HoneyNaps Selected for Korea's 2026 Global ICT Unicorn Program

First SleepTech company selected for Korea's ICT Unicorn Program FDA-cleared AI sleep diagnostic solution strengthens global expansion strategy Simultaneous selection for ICT Unicorn Program and K-VIP boosts U.S. market expansion BOSTON, May 11,...

ViGenCell's VT-EBV-N Selected for Oral Presentation at ASCO 2026

ViGenCell's VT-EBV-N Selected for Oral Presentation at ASCO 2026

Phase 2 study of EBV-specific T cell therapy to be presented at a leading oncology meeting SEOUL, South Korea, April 22, 2026 /PRNewswire/ -- ViGenCell Inc. (KOSDAQ: 308080), a clinical-stage biotechnology company based in South Korea focused on...

The Only One Selected: SUS ENVIRONMENT's Qingdao West Coast Project Named BCRC "Zero-Waste City" Typical Case

The Only One Selected: SUS ENVIRONMENT's Qingdao West Coast Project Named BCRC "Zero-Waste City" Typical Case

SHANGHAI, April 2, 2026 /PRNewswire/ -- On March 31, 2026, the 2026 International Day of Zero-Waste event was successfully held, during which SUS ENVIRONMENT's Qingdao West Coast Project was selected as a typical Zero-Waste City construction case by...

Caliway Selected to Present Preclinical Data on CBL-514 in Combination with GLP-1R Therapy at the American Diabetes Association's 2026 Scientific Sessions

Caliway Selected to Present Preclinical Data on CBL-514 in Combination with GLP-1R Therapy at the American Diabetes Association's 2026 Scientific Sessions

Preclinical research on Caliway's fat reduction drug candidate CBL-514 in combination with GLP-1R-based weight-loss therapies has been selected for presentation at the American Diabetes Association's 2026 Scientific Sessions. The presentation will...

  • 1
  • 2
  • 3
  • menu
    menu